======= ATP6V0A2 =======
== Gene Information ==
* **Official Symbol**: ATP6V0A2
* **Official Name**: ATPase H+ transporting V0 subunit a2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23545|23545]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9Y487|Q9Y487]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=ATP6V0A2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ATP6V0A2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/611716|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: The protein encoded by this gene is a subunit of the vacuolar ATPase (v-ATPase), an heteromultimeric enzyme that is present in intracellular vesicles and in the plasma membrane of specialized cells, and which is essential for the acidification of diverse cellular components. V-ATPase is comprised of a membrane peripheral V(1) domain for ATP hydrolysis, and an integral membrane V(0) domain for proton translocation. The subunit encoded by this gene is a component of the V(0) domain. Mutations in this gene are a cause of both cutis laxa type II and wrinkly skin syndrome. [provided by RefSeq, Jul 2009].
* **UniProt Summary**: Part of the proton channel of V-ATPases. Essential component of the endosomal pH-sensing machinery. May play a role in maintaining the Golgi functions, such as glycosylation maturation, by controlling the Golgi pH. In aerobic conditions, involved in intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation (PubMed:28296633). {ECO:0000269|PubMed:16415858, ECO:0000269|PubMed:18157129, ECO:0000269|PubMed:28296633}.
|V ATPase I|
|vacuolar proton-transporting V-type ATPase, V0 domain|
|vacuolar proton-transporting V-type ATPase complex|
|cellular response to increased oxygen levels|
|vacuolar acidification|
|proton-transporting ATPase activity, rotational mechanism|
|response to increased oxygen levels|
|phagosome acidification|
|transferrin transport|
|phagosome maturation|
|intracellular pH reduction|
|pH reduction|
|cellular iron ion homeostasis|
|iron ion transport|
|phagocytic vesicle membrane|
|ATPase binding|
|iron ion homeostasis|
|regulation of intracellular pH|
|acrosomal vesicle|
|insulin receptor signaling pathway|
|regulation of cellular pH|
|regulation of pH|
|cellular transition metal ion homeostasis|
|cellular monovalent inorganic cation homeostasis|
|transition metal ion transport|
|transition metal ion homeostasis|
|monovalent inorganic cation homeostasis|
|proton transmembrane transport|
|cellular response to insulin stimulus|
|regulation of macroautophagy|
|endosome membrane|
|cellular response to oxygen levels|
|response to insulin|
|cellular response to peptide hormone stimulus|
|lysosomal membrane|
|cellular response to peptide|
|regulation of autophagy|
|response to oxygen levels|
|response to peptide hormone|
|monovalent inorganic cation transport|
|response to peptide|
|transmembrane receptor protein tyrosine kinase signaling pathway|
|cellular metal ion homeostasis|
|inorganic cation transmembrane transport|
|cellular response to organonitrogen compound|
|cellular response to hormone stimulus|
|cation transmembrane transport|
|metal ion homeostasis|
|cellular cation homeostasis|
|metal ion transport|
|cellular ion homeostasis|
|inorganic ion transmembrane transport|
|cellular response to nitrogen compound|
|perinuclear region of cytoplasm|
|cation homeostasis|
|enzyme linked receptor protein signaling pathway|
|inorganic ion homeostasis|
|cellular chemical homeostasis|
|ion homeostasis|
|cation transport|
|regulation of cellular catabolic process|
|cellular homeostasis|
|response to hormone|
|ion transmembrane transport|
|regulation of catabolic process|
|response to organonitrogen compound|
|cellular response to oxygen-containing compound|
|response to nitrogen compound|
|chemical homeostasis|
|response to abiotic stimulus|
|cellular response to endogenous stimulus|
|transmembrane transport|
|ion transport|
|response to endogenous stimulus|
|protein transport|
|peptide transport|
|response to oxygen-containing compound|
|amide transport|
|establishment of protein localization|
|homeostatic process|
|nitrogen compound transport|
|immune response|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|-4.63|
|[[:results:exp90|WYE-354 6μM R02 exp90]]|-4.44|
|[[:results:exp435|JQ1 0.8μM R08 exp435]]|-3.94|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-3.47|
|[[:results:exp17|DABN 20μM R00 exp17]]|-3.4|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|-3.31|
|[[:results:exp169|BH1 1μM R04 exp169]]|-3.25|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-3.05|
|[[:results:exp466|Cannabidiol 20μM R08 exp466]]|-2.98|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-2.87|
|[[:results:exp469|CFI-400945 25μM R08 exp469]]|-2.84|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.81|
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-2.77|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-2.67|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.66|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|-2.65|
|[[:results:exp504|MK2206 4μM R08 exp504]]|-2.62|
|[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|-2.54|
|[[:results:exp24|Nocodazole 0.2μM R00 exp24]]|-2.52|
|[[:results:exp539|42°C R08 exp539]]|-2.49|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-2.42|
|[[:results:exp26|Oligomycin-A 20μM R00 exp26]]|-2.39|
|[[:results:exp401|SNS-032 25μM R07 exp401]]|-2.35|
|[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-2.35|
|[[:results:exp442|Ibrutinib 10μM R08 exp442]]|-2.32|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-2.21|
|[[:results:exp515|PU-H71 1μM R08 exp515]]|-2.21|
|[[:results:exp492|iCRT14 30μM R08 exp492]]|-2.19|
|[[:results:exp436|Dynasore 7μM R08 exp436]]|-2.18|
|[[:results:exp22|MLN-4924 2μM R00 exp22]]|-2.18|
|[[:results:exp382|Palbociclib 1μM R07 exp382]]|-2.18|
|[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|-2.17|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.16|
|[[:results:exp151|SGC0946 7μM R03 exp151]]|-2.16|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.15|
|[[:results:exp4|Actinomycin-D 0.01μM R00 exp4]]|-2.07|
|[[:results:exp455|Benzoate 10000μM R08 exp455]]|-2.06|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|-2.06|
|[[:results:exp470|Chloroquine 32μM R08 exp470]]|-2.04|
|[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|-2.03|
|[[:results:exp487|Hinokiflavone 12μM R08 exp487]]|-1.98|
|[[:results:exp128|GSK591 2.6μM R03 exp128]]|-1.96|
|[[:results:exp456|Benzoate 20000μM R08 exp456]]|-1.95|
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-1.94|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-1.93|
|[[:results:exp182|IU1-47 25μM R04 exp182]]|-1.93|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-1.89|
|[[:results:exp160|Ribavirin 10 to 15μM on day4 R04 exp160]]|-1.87|
|[[:results:exp81|Selumetinib 20μM R02 exp81]]|-1.86|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|-1.85|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.8|
|[[:results:exp459|Bleomycin 5μM R08 exp459]]|-1.8|
|[[:results:exp433|LJH685 50μM R08 exp433]]|-1.75|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|-1.75|
|[[:results:exp527|Tanespimycin 14μM R08 exp527]]|-1.75|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-1.72|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|1.7|
|[[:results:exp301|VER-155008 3.9μM R06 exp301]]|1.96|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|2|
|[[:results:exp288|HMS-I2 10μM R06 exp288]]|2.09|
^Gene^Correlation^
|[[:human genes:w:wdr7|WDR7]]|0.639|
|[[:human genes:p:prim1|PRIM1]]|0.583|
|[[:human genes:z:zfat|ZFAT]]|0.546|
|[[:human genes:t:tgfbrap1|TGFBRAP1]]|0.453|
|[[:human genes:a:atp6v1d|ATP6V1D]]|0.447|
|[[:human genes:g:gpr107|GPR107]]|0.443|
|[[:human genes:a:arl1|ARL1]]|0.434|
|[[:human genes:a:atp6v1g1|ATP6V1G1]]|0.43|
|[[:human genes:p:pi4kb|PI4KB]]|0.413|
|[[:human genes:s:slc39a9|SLC39A9]]|0.412|
|[[:human genes:v:vps54|VPS54]]|0.403|
|[[:human genes:a:atp6v0b|ATP6V0B]]|0.402|
Global Fraction of Cell Lines Where Essential: 3/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|2/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1315
* **Expression level (log2 read counts)**: 6.82
{{:chemogenomics:nalm6 dist.png?nolink |}}